Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anish Thomas

Showing results (21-30 of 167) with videos related to

Pageof 17
Sort By:
Hematology/Oncology Clinics of North America|April 24, 2012
Tyrosine kinase inhibitors in lung cancerAnish Thomas, Arun Rajan, Giuseppe Giaccone
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
Frontiers in Oncology|May 22, 2014
Novel biologic therapies for thymic epithelial tumorsYuanbin Chen, Helen Gharwan, Anish Thomas
The Journal of Clinical Investigation|April 18, 2018
The evolving landscape of predictive biomarkers of response to PARP inhibitorsAnish Thomas, Junko Murai, Yves Pommier
Frontiers in Oncology|May 18, 2026
Reframing small cell lung cancer: therapeutic lessons from hematologic malignanciesKanak Parmar, Ira Surolia, Anish Thomas
The Lancet. Oncology|June 15, 2016
Antibody-drug conjugates for cancer therapyAnish Thomas, Beverly A Teicher, Raffit Hassan
Translational Lung Cancer Research|February 3, 2017
Metastatic lung cancer in the age of targeted therapy: improving long-term survivalJaydira Del Rivero, Lindsey Enewold, Anish Thomas
Lung Cancer Management|October 25, 2019
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?Dmitriy Sonkin, Anish Thomas, Beverly A Teicher
Cancer Genetics|June 23, 2024
Cancer treatments: Past, present, and futureDmitriy Sonkin, Anish Thomas, Beverly A Teicher
Anticancer Research|January 10, 2014
From platinum compounds to targeted therapies in advanced thoracic malignanciesMarko Jakopovic, Anish Thomas, Ariel Lopez-Chavez
Pageof 17

Showing results (21-30 of 167) with videos related to

Sort By:
Pageof 17
Hematology/Oncology Clinics of North America|April 24, 2012
Tyrosine kinase inhibitors in lung cancerAnish Thomas, Arun Rajan, Giuseppe Giaccone
The New England Journal of Medicine|December 14, 2011
Myeloma and second primary cancersOla Landgren, Anish Thomas, Sham Mailankody
Frontiers in Oncology|May 22, 2014
Novel biologic therapies for thymic epithelial tumorsYuanbin Chen, Helen Gharwan, Anish Thomas
The Journal of Clinical Investigation|April 18, 2018
The evolving landscape of predictive biomarkers of response to PARP inhibitorsAnish Thomas, Junko Murai, Yves Pommier
Frontiers in Oncology|May 18, 2026
Reframing small cell lung cancer: therapeutic lessons from hematologic malignanciesKanak Parmar, Ira Surolia, Anish Thomas
The Lancet. Oncology|June 15, 2016
Antibody-drug conjugates for cancer therapyAnish Thomas, Beverly A Teicher, Raffit Hassan
Translational Lung Cancer Research|February 3, 2017
Metastatic lung cancer in the age of targeted therapy: improving long-term survivalJaydira Del Rivero, Lindsey Enewold, Anish Thomas
Lung Cancer Management|October 25, 2019
Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?Dmitriy Sonkin, Anish Thomas, Beverly A Teicher
Cancer Genetics|June 23, 2024
Cancer treatments: Past, present, and futureDmitriy Sonkin, Anish Thomas, Beverly A Teicher
Anticancer Research|January 10, 2014
From platinum compounds to targeted therapies in advanced thoracic malignanciesMarko Jakopovic, Anish Thomas, Ariel Lopez-Chavez
Pageof 17